Compare Ally Financial Inc (ALLY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Ally Financial Inc trades at $43.92 (market cap $13.37B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Ally Financial Inc pays a 2.73% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ally Financial Inc nearer its low. Which is the better fit depends on your goals.
| ALLY | XBI | |
|---|---|---|
Market Cap | $13.37B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $47.25 | $164.28 |
52-Week Low | $35.96 | $86.92 |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $44.14, up 0.8% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed earnings, beating estimates in Q1 2026 but missing in Q2, while maintaining a P/E of 10.34 and P/B of 0.99, indicating potential undervaluation. Recent news includes insider sales and corporate recognitions, alongside a declared $0.30 dividend payable in August 2026.
The outlook for ALLY is cautiously optimistic, with a consensus price target of $54.40 offering ~23% upside, though risks from higher provisions and macroeconomic pressures persist. Investment appeal lies in its low valuation and dividend, but investors must weigh credit risks and interest rate sensitivity against growth in auto finance and digital banking strengths.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
